USPTO 2015–2025 USPTO PatentsView US Corporation

Theravance Biopharma R&D IP, Llc

USPTO PatentsView assignee record - 239 granted patents across 16 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Explore the portfolio See the ranking

239

Total patents granted

CPC technology areas

15.1

Avg claims per patent

-29%

5-year filing velocity

The verdict

Theravance holds 239 US patents across 16 technology areas, rank #1,711 of 50,000 tracked assignees.

#1,711
of 50,000 US assignees by volume: Top 21%
by Innovation Score (46.5/100): 15.1
avg claims per patent: -29%
filing velocity, last 5 yrs

Portfolio overview

Theravance Biopharma R&D IP, Llc has been granted 239 US utility patents between 2015 and 2025, placing Theravance Biopharma R&D IP, Llc at rank #1,711 across all assignees tracked by PlainPatent. This portfolio spans 16 distinct Cooperative Patent Classification (CPC) subclasses, averaging 15.1 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Theravance Biopharma R&D IP, Llc is one of the more focused assignees in the PatentsView dataset. By volume, Theravance sits between DANA Heavy Vehicle Systems Group, Llc (240 patents, rank #1,707) and Children's Hospital Medical Center (238 patents, rank #1,715) - the closest US assignees by grant volume. The composite Innovation Score of 46.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 99 grants, compared with 140 in the 2015–2019 window, a -29% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Theravance Biopharma R&D IP, Llc's 15.1 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 16 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Theravance Biopharma R&D IP, Llc against peers pursuing similar technology classes.

DANA Heavy Vehicl…

240
Entit Software

239
Medtronic Xomed

239
Nikkiso

239
Vorwerk & Interho…

239
ZKW Group

239
Theravance Biopha… ◀

239
Alipay (Hangzhou)…

238
Children's Hospit…

238

What this shows Theravance holds 239 patents at rank #1,711, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Theravance

By rank, the assignees closest to #1,711 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Theravance's primary technology class.

Theravance's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

46 Top 21% higher than 79% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Theravance Biopharma R&D IP, Llc patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	39	16.3%
2016	22	9.2%
2017	27	11.3%
2018	23	9.6%
2019	29	12.1%
2020	24	10.0%
2021	20	8.4%
2022	14	5.9%
2023	27	11.3%
2024	7	2.9%
2025	7	2.9%

Which technologies does Theravance Biopharma R&D IP, Llc patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 229

C07D - HETEROCYCLIC COMPOUNDS 222

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 206

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 51

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 38

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 13

C30B - SINGLE-CRYSTAL GROWTH ; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL ; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE ; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WI 6

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 6

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 5

Y02P - CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS 5

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 4

C12P - FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 4

C09K - MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE 2

A01N - PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF ; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES ; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS 2

Y10T - TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION 1

Top 15 of 16 technology areas

Patent Moat Analysis

Portfolio Volume Moderate

Tech Breadth Focused

Claim Depth Standard

Velocity Declining

Where it ranks

Overall rank by patents

#1,711

Across all tracked assignees

Innovation Score

46.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Theravance Biopharma R&D IP, Llc hold?

Theravance Biopharma R&D IP, Llc holds 239 US granted patents filed between 2015 and 2025, spanning 16 technology areas.

What is Theravance Biopharma R&D IP, Llc's Innovation Score?

Theravance Biopharma R&D IP, Llc has an Innovation Score of 46.5 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Theravance Biopharma R&D IP, Llc focus on?

Theravance Biopharma R&D IP, Llc's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 229 patents. The company has filed patents in 16 CPC subclasses total.

Is Theravance Biopharma R&D IP, Llc's patent filing rate increasing or decreasing?

Theravance Biopharma R&D IP, Llc's recent filing velocity is -29% compared to the prior five-year period. Filing activity has slowed relative to earlier years.

What does claim depth mean for Theravance Biopharma R&D IP, Llc's patents?

Theravance Biopharma R&D IP, Llc's patents average 15.1 claims each. This falls within the standard range, providing solid legal coverage.

How is the Theravance Biopharma R&D IP, Llc patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Theravance's 239 grants land it in the top 21% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Theravance ranks #1,711 of 50,000. Top 50 holders
Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled byPlainPatent Editorial, US Patent Intelligence Editorial Team · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.